lopinavir has been researched along with Viremia in 27 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 12 (44.44) | 29.6817 |
2010's | 15 (55.56) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fernández Cooke, E; Holguín, Á; Jiménez De Ory, S; Navarro, ML; Prieto, L; Ramos, JT; Rojas Sánchez, P | 1 |
Bacchetti, P; Gandhi, M; Horng, H; Jin, C; Kerr, S; Koss, CA; Kuncze, K; Louie, A; Phung, N; Pintye, J; Prasitsuebsai, W; Singtoroj, T; Sohn, AH; Teeraananchai, S | 1 |
Blanco, J; Clotet, B; Gómez-Mora, E; Hernández-Rodríguez, A; Marfil, S; Martínez-Bonet, M; Martinez-Picado, J; Matas, L; Moltó, J; Morón-López, S; Muñoz-Fernández, MA; Puertas, MC; Santos, JR; Urrea, V | 1 |
Boinett, R; Brooks, K; Buziba, N; Coetzer, M; DeLong, A; Diero, L; Emonyi, W; Hogan, J; Kantor, R; Kemboi, E; Obonge, S; Orido, M; Reitsma, M; Rono, M; Schreier, L | 1 |
Perelson, AS; Zhang, J | 1 |
Bosch, RJ; Eron, JJ; Kuritzkes, DR; Taiwo, B; Vardhanabhuti, S | 1 |
Hull, MW; Lima, VD; Montaner, JS; Richard Harrigan, P; Sierra-Madero, J; Singer, J; Wood, E; Wu, Z | 1 |
Arribas, JR; Bernardino, JI; Estébanez, M; González-García, JJ; Mingorance, J; Montes, ML; Pérez-Valero, I; Stella-Ascariz, N; Zamora, FX | 1 |
Haagmans, BL; Koopmans, MP; Koulouris, NG; Koutsoukou, A; Osterhaus, AD; Pontikis, K; Raj, VS; Spanakis, N; Tsakris, A; Tsiodras, S | 1 |
Abrams, EJ; Castel, S; Coovadia, A; Kuhn, L; Maartens, G; McIlleron, H; Moholisa, RR; Patel, F; Pinillos, F; Schomaker, M; Strehlau, R; Wiesner, L | 1 |
Andreoni, M; Antinori, A; Castagna, A; Ceccherini-Silberstein, F; Celesia, BM; Cozzi-Lepri, A; d'Arminio Monforte, A; De Luca, A; Galli, M; Gianotti, N; Mussini, C; Pinnetti, C; Spagnuolo, V | 1 |
Llenas-García, J; Pulido Ortega, F | 1 |
Delgado, R | 1 |
Pacios, E | 1 |
Andrade-Villanueva, J; Barnard, RJ; Berger, DS; Cooper, DA; Dejesus, E; Dinubile, MJ; Eron, JJ; Fätkenheuer, G; Kumar, PN; Leavitt, R; Miller, MD; Nguyen, BY; Rodgers, AJ; Shaughnessy, MA; Sklar, P; Walker, ML; Workman, C; Xu, X; Youle, M; Young, B; Zajdenverg, R | 1 |
Abrams, EJ; Coovadia, A; Hu, CC; Hunt, G; Kuhn, L; Martens, L; Meyers, T; Morris, L; Sherman, G; Stehlau, R; Tsai, WY | 1 |
D'Avolio, A; Fuchs, D; Gisslén, M; Hagberg, L; Svennerholm, B; Verhofstede, C; Watson, V; Yilmaz, A | 1 |
Dunn, DT; Gibb, DM; Gilks, CF; Kaleebu, P; Kasirye, R; Kikaire, B; Mambule, I; Musana, H; Pillay, D; Reid, A; Robertson, V; Spyer, M; Ssali, F; Walker, AS; Yirrell, D | 1 |
Fusco, G; Liao, Q; Paulsen, D; Ross, L; Shaefer, M; St Clair, M | 1 |
Albert, J; Blaxhult, A; Brandin, E; Broström, C; Gisslen, M; Gyllensten, K; Hagberg, L; Lindborg, L; Tuvesson, B | 1 |
Adorni, F; Bini, T; Bongiovanni, M; Capetti, A; Cargnel, A; Chiesa, E; Cicconi, P; Cordier, L; d'Arminio Monforte, A; Landonio, S; Meraviglia, P; Rusconi, S; Tordato, F | 1 |
Adorni, F; Bini, T; Bongiovanni, M; Chiesa, E; Cicconi, P; Monforte d'Arminio, A | 1 |
Dalmau, D; Ferrer, E; Gatell, JM; Iniguez, D; Knobel, H; Leon, A; Niubo, J; Podzamczer, D; Polo, C; Ruiz, I | 1 |
Arribas, JR; Delgado, R; McKinnon, JE; Mellors, JW; Pulido, F | 1 |
Amoroso, A; Chan-Tack, KM; Kopack, AM; Polk, C | 1 |
Hanna, GJ; Podsadecki, TJ; Rode, RA; Tousset, EP; Vrijens, BC | 1 |
Bay, MB; Jeffman, MW; Lazzaretti, RK; Mattevi, VS; Sprinz, E | 1 |
2 review(s) available for lopinavir and Viremia
Article | Year |
---|---|
[Lopinavir/ritonavir monotherapy as a simplification strategy in the treatment of HIV-1 infection].
Topics: Anti-HIV Agents; Clinical Trials as Topic; Cost Control; Developing Countries; Drug Combinations; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lopinavir; Multicenter Studies as Topic; Pilot Projects; Prospective Studies; Pyrimidinones; Randomized Controlled Trials as Topic; Ritonavir; Treatment Outcome; Viral Load; Viremia; Virus Replication | 2008 |
[Lopinavir/ritonavir monotherapy for the treatment of HIV-1 infection: the emergence of resistance].
Topics: Anti-HIV Agents; Clinical Trials as Topic; Drug Combinations; Drug Resistance, Multiple, Viral; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Incidence; Lopinavir; Mutation, Missense; Pilot Projects; Point Mutation; Pyrimidinones; Randomized Controlled Trials as Topic; Ritonavir; Viremia | 2008 |
10 trial(s) available for lopinavir and Viremia
Article | Year |
---|---|
Impact of intensification with raltegravir on HIV-1-infected individuals receiving monotherapy with boosted PIs.
Topics: Adult; Antiretroviral Therapy, Highly Active; Darunavir; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Immunity, Cellular; Inflammation; Lopinavir; Lymphocyte Activation; Male; Middle Aged; Pilot Projects; Proof of Concept Study; Raltegravir Potassium; RNA, Viral; Viremia; Virus Replication | 2018 |
Comparing the efficacy of efavirenz and boosted lopinavir using viremia copy-years.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Treatment Outcome; Viral Load; Viremia | 2014 |
Inflammatory, procoagulant markers and HIV residual viremia in patients receiving protease inhibitor monotherapy or triple drug therapy: a cross-sectional study.
Topics: Adult; Biomarkers; Cross-Sectional Studies; Cytokines; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Inflammation; Lopinavir; Male; Middle Aged; Ritonavir; Sulfonamides; Viremia | 2014 |
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.
Topics: Adult; Anti-HIV Agents; Cholesterol, LDL; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Pyrrolidinones; Raltegravir Potassium; Ritonavir; RNA, Viral; Treatment Outcome; Viremia | 2010 |
Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial.
Topics: Anti-HIV Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Male; Maternal Exposure; Nevirapine; Protease Inhibitors; Pyrimidinones; RNA, Viral; Stavudine; Treatment Outcome; Viremia | 2010 |
Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy.
Topics: Adult; Albumins; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Central Nervous System Infections; Cross-Over Studies; Cyclohexanes; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Immunoglobulin G; Lopinavir; Male; Maraviroc; Middle Aged; Neopterin; Peptide Fragments; Polymerase Chain Reaction; Ritonavir; RNA, Viral; Triazoles; Viral Load; Viremia; Virus Replication | 2010 |
Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA).
Topics: Adult; Africa; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Mutation; Ritonavir; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Viremia | 2012 |
Virological success of lopinavir/ritonavir salvage regimen is affected by an increasing number of lopinavir/ritonavir-related mutations.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Mutation; Proportional Hazards Models; Pyrimidinones; Ritonavir; Salvage Therapy; Viremia | 2003 |
Early virological failure with a combination of tenofovir, didanosine and efavirenz.
Topics: Adenine; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Didanosine; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Mutation; Organophosphonates; Oxazines; Pyrimidinones; RNA, Viral; Tenofovir; Time Factors; Treatment Failure; Viremia | 2005 |
Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia.
Topics: Adult; Aged; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Prospective Studies; Pyrimidinones; Ritonavir; RNA, Viral; Treatment Refusal; Viral Load; Viremia | 2007 |
15 other study(ies) available for lopinavir and Viremia
Article | Year |
---|---|
Impact of lopinavir-ritonavir exposure in HIV-1 infected children and adolescents in Madrid, Spain during 2000-2014.
Topics: Adolescent; CD4 Lymphocyte Count; CD4-CD8 Ratio; Child; Child, Preschool; Cohort Studies; Drug Combinations; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Host-Pathogen Interactions; Humans; Infant; Infant, Newborn; Lopinavir; Male; Mutation; Ritonavir; Spain; Treatment Outcome; Viral Load; Viremia | 2017 |
Brief Report: Lopinavir Hair Concentrations Are the Strongest Predictor of Viremia in HIV-Infected Asian Children and Adolescents on Second-Line Antiretroviral Therapy.
Topics: Adolescent; Anti-HIV Agents; Asian People; CD4 Lymphocyte Count; Child; Drug Monitoring; Female; Hair; HIV Infections; Humans; Indonesia; Longitudinal Studies; Lopinavir; Male; Medication Adherence; Predictive Value of Tests; Thailand; Vietnam; Viral Load; Viremia | 2017 |
HIV-1 second-line failure and drug resistance at high-level and low-level viremia in Western Kenya.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cross-Sectional Studies; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Kenya; Lopinavir; Male; Middle Aged; pol Gene Products, Human Immunodeficiency Virus; Ritonavir; Sequence Analysis, DNA; Treatment Failure; Viral Load; Viremia | 2018 |
Contribution of follicular dendritic cells to persistent HIV viremia.
Topics: Dendritic Cells, Follicular; Drug Combinations; HIV Infections; HIV-1; Humans; Kinetics; Lamivudine; Lopinavir; Models, Biological; Ritonavir; Stavudine; Viral Load; Viremia; Virus Release | 2013 |
Phylogenetic evidence of HIV-1 sequence evolution in subjects with persistent low-level viraemia.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Evolution, Molecular; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Mutation; Phylogeny; pol Gene Products, Human Immunodeficiency Virus; Retrospective Studies; Ritonavir; RNA, Viral; Viral Load; Viremia | 2015 |
Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen.
Topics: Antiviral Agents; Coronavirus Infections; Drug Combinations; Drug Therapy, Combination; Greece; Humans; Lopinavir; Male; Middle East Respiratory Syndrome Coronavirus; Phylogeny; Respiratory Tract Infections; Ribavirin; Ritonavir; Viremia; Virus Shedding | 2014 |
Effect of Lopinavir and Nevirapine Concentrations on Viral Outcomes in Protease Inhibitor-experienced HIV-infected Children.
Topics: Child, Preschool; Drug Monitoring; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Lopinavir; Nevirapine; Treatment Outcome; Viral Load; Viremia | 2016 |
Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Darunavir; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Kaplan-Meier Estimate; Lopinavir; Male; Middle Aged; Outcome Assessment, Health Care; Proportional Hazards Models; Ritonavir; RNA, Viral; Viral Load; Viremia; Young Adult | 2017 |
[Regimen simplification: lopinavir/ritonavir with or without efavirenz].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV Infections; Humans; Lopinavir; Pyrimidinones; Ritonavir; Treatment Outcome; Viral Load; Viremia | 2009 |
Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia.
Topics: Carbamates; Cross-Sectional Studies; Drug Resistance, Viral; Furans; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Microbial Sensitivity Tests; Mutation; Phenotype; Pyrimidinones; Retrospective Studies; RNA, Viral; Sulfonamides; Viremia | 2002 |
pol gene sequence variation in Swedish HIV-2 patients failing antiretroviral therapy.
Topics: Adolescent; Adult; Africa, Western; Amino Acid Sequence; Amino Acid Substitution; Anti-HIV Agents; Codon; Drug Resistance, Multiple, Viral; Evolution, Molecular; Female; Genes, pol; Genetic Variation; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-2; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Molecular Sequence Data; Mutation, Missense; Nelfinavir; Prospective Studies; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Sequence Alignment; Sequence Homology, Amino Acid; Sweden; Treatment Failure; Viremia; Zidovudine | 2003 |
Lopinavir/ritonavir vs. indinavir/ritonavir in antiretroviral naive HIV-infected patients: immunovirological outcome and side effects.
Topics: Adult; Antiretroviral Therapy, Highly Active; Cholesterol; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Male; Pyrimidinones; Retrospective Studies; Ritonavir; RNA, Viral; Viremia | 2004 |
The level of persistent HIV viremia does not increase after successful simplification of maintenance therapy to lopinavir/ritonavir alone.
Topics: Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Longitudinal Studies; Lopinavir; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Treatment Failure; Viral Load; Viremia | 2006 |
Induction therapy with enfuvirtide-based highly active antiretroviral therapy in a patient with acute HIV-1 infection.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Emtricitabine; Enfuvirtide; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Lopinavir; Male; Organophosphonates; Peptide Fragments; Pyrimidinones; Ritonavir; Tenofovir; Viral Load; Viremia | 2007 |
Lopinavir/ritonavir monotherapy as maintenance treatment in HIV-infected individuals with virological suppression: results from a pilot study in Brazil.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Brazil; CD4 Lymphocyte Count; Cytochrome P-450 CYP3A; Drug Administration Schedule; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Pilot Projects; Polymorphism, Genetic; Pyrimidinones; Ritonavir; RNA, Viral; Viral Load; Viremia | 2008 |